User:Mr. Ibrahem/Olaparib

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Olaparib
Clinical data
Trade namesLynparza, others
Other namesAZD-2281, MK-7339, KU0059436
AHFS/Drugs.comMonograph
MedlinePlusa614060
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
Drug classPARP inhibitor[1]
Legal status
Legal status
Identifiers
  • 4-[(3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl) -4-fluorophenyl]methyl(2H)phthalazin-1-one
Chemical and physical data
FormulaC24H23FN4O3
Molar mass434.471 g·mol−1
3D model (JSmol)
  • c4cccc2c4c(n[nH]c2=O)Cc(ccc1F)cc1C(=O)N3CCN(CC3)C(=O)C5CC5
  • InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30) checkY
  • Key:FDLYAMZZIXQODN-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Olaparib, sold under the brand name Lynparza, is a medication used to treat ovarian cancer, fallopian tube cancer, and peritoneal cancer.[4][1] It is used in cases that have failed other treatments and are likely BRCA mutation positive.[4] It is taken by mouth.[1]

Common side effects include tiredness, nausea, diarrhea, heartburn, cough, headache, shortness of breath, low white blood cells, and low platelets.[7] Other side effects may include myelodysplastic syndrome and pneumonitis.[4] It should not be used when breastfeeding or pregnant.[7][4] It is a PARP inhibitor and works by blocking the ability of cancer cells to repair their DNA.[1]

Olaparib was approved for medical use in Europe and the United States in 2014.[4][7] In the United Kingdom a dose of 300 mg twice per day costs about £4,600 for 4 weeks as of 2021.[1] This amount in the United States costs about 14,000 USD.[8]

References[edit]

  1. ^ a b c d e f BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1051. ISBN 978-0857114105.
  2. ^ "Lynparza 50 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Archived from the original on 23 September 2020. Retrieved 13 April 2020.
  3. ^ "Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Archived from the original on 26 September 2020. Retrieved 13 April 2020.
  4. ^ a b c d e f g "Lynparza- olaparib capsule". DailyMed. 27 September 2018. Archived from the original on 26 October 2021. Retrieved 30 December 2019.
  5. ^ "Lynparza- olaparib tablet, film coated". DailyMed. 1 June 2019. Archived from the original on 25 October 2021. Retrieved 30 December 2019.
  6. ^ "Lynparza EPAR". European Medicines Agency (EMA). Archived from the original on 24 September 2020. Retrieved 6 October 2020.
  7. ^ a b c d "Lynparza EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 24 September 2020. Retrieved 13 April 2020.
  8. ^ "Lynparza Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 January 2021. Retrieved 7 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Olaparib&oldid=1157808395"